Akeso, Inc. announced record-high drug sales revenue of RMB 1,803.2 million for the first half of 2026, a 28.7% increase year-over-year, driven by expanded market access through inclusion in China's National Reimbursement Drug List and new drug approvals. The company advanced its global immuno-oncology 2.0 strategy with key clinical successes, including approvals for ivonescimab in lung and biliary tract cancers and positive Phase III trial results demonstrating survival benefits. Akeso is also developing a therapeutic matrix combining bispecific antibodies and antibody-drug conjugates, with multiple ongoing global registrational trials and collaborations. Looking ahead, Akeso is expanding into autoimmune, respiratory, and CNS diseases with novel bispecific antibodies and leveraging AI for drug discovery to maintain innovation leadership.
Comvita reported a net profit after tax (NPAT) of $7.7 million for the fiscal year ending June 30, 2026, marking a return to profitability. The company also significantly reduced its debt, normalized inventory levels, and restored positive cash flow....
Six months after the US and Israel launched combat operations in Iran, the conflict remains a stalemate with no clear resolution. The Trump administration has shifted from military action to economic pressure, including secondary sanctions, aiming to...
The U.S. SEC declared Evernorth Holdings' Form S-4 registration effective, allowing Armada Acquisition Corp. II shareholders to vote on the proposed merger on September 30, 2026. This merger would create a Nasdaq-listed company under the ticker XRPN,...
VictoryShares US Value Momentum ETF (ULVM) received a Hold rating because, despite its strong year-to-date performance, it faces long-term vulnerabilities. The ETF combines value and momentum investment strategies but leans towards low volatility, wh...
Bitcoin DeFi lending involves depositing BTC-related assets as collateral to borrow or supply liquidity, with returns from borrower interest or fees. Different lending models—pooled, isolated, stablecoin-backed, native BTC, and custodial—vary in risk...
